Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study

https://doi.org/10.1016/S0168-8278(98)80237-7Get rights and content

Abstract

Background/Aims: In the current state of knowledge of the pathophysiology of hepatic encephalopathy, a reduction in hyperammonemia is the most important evidence of effective treatment. Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic encephalopathy in a randomized, double-blind, placebo-controlled clinical trial.

Methods: Oral L-ornithine-L-aspartate was administered three times daily at fixed times for 14 consecutive days in a total dose of 18 g per day. The design was chosen to prevent an increase in ammonia induced by a protein meal of 0.25 g/kg body weight, given at the start of the daily treatment period. Efficacy variables were: fasting and postprandial ammonia concentration, Number-Connection-Test time, mental state grades, and a Portosystemic Encephalopathy Index. Analyses were based on the total study sample of 32 placebo- and 34 L-ornithine-L-aspartate-treated patients as well as on the subgroup samples in the overt (20 placebo- and 23 L-ornithine-L-aspartate-treated) and subclinical hepatic encephalopathy (12 placebo- and 11 L-ornithine-L-aspartate-treated) patients.

Results: Number Connection Test performance times (p<0.01) as well as fasting (p<0.01) and postprandial (p<0.05) venous blood ammonia concentrations in the L-ornithine-L-aspartate-treated group showed improvement in comparison to placebo. Also, the mental state grade (p<0.05) and the Portosystemic Encephalopathy Index (p<0.01), improved to a much greater degree in the L-ornithine-L-aspartate group than in the placebo group. Adverse events were observed in neither the placebo nor the L-ornithine-L-aspartate-treated patients.

Conclusion: Oral L-ornithine-L-aspartate is a safe, well-tolerated treatment with a good compliance rate and a beneficial therapeutic effect in patients with cirrhosis and stable, overt, chronic hepatic encephalopathy.

References (24)

  • HO Conn

    The theoretic therapy of hepatic encephalopathy

  • G Kircheis et al.

    Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study

    Hepatology

    (1997)
  • Cited by (144)

    • Endogenous Metabolic Modulators: Emerging Therapeutic Potential of Amino Acids

      2020, iScience
      Citation Excerpt :

      LOLA promotes urea synthesis and reduces blood ammonia, a key toxin in HE pathogenesis (Gebhardt et al., 1997; Kircheis and Luth, 2019). LOLA has potential as a treatment for overt and minimal HE (Alvares-Da-Silva et al., 2014; Kircheis et al., 1997; Sharma et al., 2014; Stauch et al., 1998). In a double-blind randomized trial, LOLA (six months) versus placebo significantly improved secondary HE prophylaxis among patients with cirrhosis (n = 73) (Varakanahalli et al., 2018).

    • Neuropsychiatric performance in patients with cirrhosis: Who is “normal”?

      2017, Journal of Hepatology
      Citation Excerpt :

      Thus, in many ways, the definition of normal neuropsychiatric performance has been largely dependent on the definition of minimal HE (and thus its absence) and on the availability and the features of pertinent, local normative data. A summary of the definitions of minimal HE and/or normal neuropsychiatric performance in a set of relevant studies published between 1989 and 2016 is presented in Supplementary Table 1 [8,9,27–61]. While this literature review does not aim at being comprehensive, it provides a snapshot of the variability of definitions utilised over a period of approximately 30 years.

    View all citing articles on Scopus
    View full text